argenx to advance celiac candidate FB102 to Phase 3 as Phase 2 met primary endpoint, end Phase 3 in Sjögren's

 

argenx to advance celiac candidate FB102 to Phase 3 after Phase 2 met primary endpoint and end Phase 3 UNITY study in Sjögren's disease

• argenx discontinues Phase 3 UNITY study of efgartigimod SC in Sjögren's disease after interim analysis found trial unlikely to meet its primary endpoint

https://finviz.com/stock?t=ARGX&p=d